Our findings provide possibilities to extend PARP inhibitors for the treatment of BRCA-WT breast cancer patients or PARP inhibitor-resistant patients through cotreatment of CCL3, β-catenin inhibitors, anti-RANKL antibody, or bisphosphonates. Here, PARP1 is linked to breast carcinoma.